These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31990387)

  • 21. Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.
    Thomas AM; Gerogianni A; McAdam MB; Fløisand Y; Lau C; Espevik T; Nilsson PH; Mollnes TE; Barratt-Due A
    J Immunol; 2019 Sep; 203(6):1571-1578. PubMed ID: 31413105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease.
    Chudwin DS; Papierniak C; Lint TF; Korenblit AD
    Clin Immunol Immunopathol; 1994 May; 71(2):199-202. PubMed ID: 8181189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chlorine inhalation induces acute chest syndrome in humanized sickle cell mouse model and ameliorated by postexposure hemopexin.
    Alishlash AS; Sapkota M; Ahmad I; Maclin K; Ahmed NA; Molyvdas A; Doran S; Albert CJ; Aggarwal S; Ford DA; Ambalavanan N; Jilling T; Matalon S
    Redox Biol; 2021 Aug; 44():102009. PubMed ID: 34044323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human sickle cell blood modulates endothelial heme oxygenase activity: effects on vascular adhesion and reactivity.
    Bains SK; Foresti R; Howard J; Atwal S; Green CJ; Motterlini R
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):305-12. PubMed ID: 19965783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
    Barbu EA; Dominical VM; Mendelsohn L; Thein SL
    PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement in Sickle Cell Disease: Are We Ready for Prime Time?
    Varelas C; Tampaki A; Sakellari I; Anagnostopoulos Α; Gavriilaki E; Vlachaki E
    J Blood Med; 2021; 12():177-187. PubMed ID: 33790681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
    Gerotziafas GT; Van Dreden P; Chaari M; Galea V; Khaterchi A; Lionnet F; Stankovic-Stojanovic K; Blanc-Brude O; Woodhams B; Maier-Redelsperger M; Girot R; Hatmi M; Elalamy I
    Thromb Haemost; 2012 Jun; 107(6):1044-52. PubMed ID: 22535498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.
    Leaderer D; Cashman SM; Kumar-Singh R
    J Gene Med; 2015; 17(6-7):101-15. PubMed ID: 25917932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
    Lopes FC; Traina F; Almeida CB; Leonardo FC; Franco-Penteado CF; Garrido VT; Colella MP; Soares R; Olalla-Saad ST; Costa FF; Conran N
    Haematologica; 2015 Jun; 100(6):730-9. PubMed ID: 25769545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.
    Abraham AA; Lang H; Meier ER; Nickel RS; Dean M; Lawal N; Speller-Brown B; Wang Y; Kean L; Bollard CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27601. PubMed ID: 30609269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation.
    Keleku-Lukwete N; Suzuki M; Otsuki A; Tsuchida K; Katayama S; Hayashi M; Naganuma E; Moriguchi T; Tanabe O; Engel JD; Imaizumi M; Yamamoto M
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12169-74. PubMed ID: 26371321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
    Ulug P; Vasavda N; Kumar R; Keir L; Awogbade M; Cunningham J; Rees DC; Menzel S; Thein SL
    Am J Hematol; 2008 Sep; 83(9):714-6. PubMed ID: 18615556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
    Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
    N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia.
    Barros MM; Yamamoto M; Figueiredo MS; Cançado R; Kimura EY; Langhi DM; Chiattone CS; Bordin JO
    Transfusion; 2009 Jan; 49(1):154-60. PubMed ID: 18954403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discriminating complement-mediated acute transfusion reaction for type O+ red blood cells transfused into a B+ recipient with the complement hemolysis using human erythrocytes (CHUHE) assay.
    Cunnion KM; Hair PS; Krishna NK; Whitley PH; Goldberg CL; Fadeyi EA; Maes LY
    Transfusion; 2016 Jul; 56(7):1845-8. PubMed ID: 26997226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.
    Nuutila J; Jalava-Karvinen P; Hohenthal U; Kotilainen P; Pelliniemi TT; Nikoskelainen J; Lilius EM
    Hum Immunol; 2013 May; 74(5):522-30. PubMed ID: 23376460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.